Figure 8: LASV mAbs ontogeny and binding kinetics. | Nature Communications

Figure 8: LASV mAbs ontogeny and binding kinetics.

From: Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits

Figure 8

Antibody heavy- and light-chain constructs were sequenced and consensus immunoglobulin sequences spanning framework 1 through 4, and CDRs 1–3 were subjected to in silico analysis using IMGT/V-QUEST and the abYsis integrated antibody analysis and prediction software. (a) Use of heavy and light chains by neutralizing (left) and non-neutralizing mAbs. (b) Dissociation constants of neutralizing and non-neutralizing mAbs. (c) Divergence from presumed germline genes of heavy and light chains of neutralizing and non-neutralizing mAbs. (d) CDR-H3 lengths of neutralizing and non-neutralizing mAbs. (e) Similarity to presumed germline genes of heavy and light chains of human mAbs as a function of time between infection and PBMC collection. Neut., neutralizing; Non neut., non-neutralizing.

Back to article page